Last updated: April 25, 2026
Who Supplies Amiodarone Hydrochloride to the Pharmaceutical Market?
Amiodarone hydrochloride is a widely manufactured, off-patent generic active pharmaceutical ingredient (API) used for arrhythmia treatment. Because the API is commoditized and the supply chain often spans multiple intermediates (notably amiodarone free base) plus salt-form conversion, “suppliers” in practice fall into three buckets: API manufacturers, contract manufacturers (API-to-finish), and finished-dose branded/generic product holders that source the API from qualified feeds.
Which API manufacturers supply amiodarone hydrochloride?
The most commercially relevant “suppliers” are API producers that appear in global regulatory and quality systems (DMF holders, CEP holders, and CGMP API manufacturing sites). The following are commonly observed sources of amiodarone hydrochloride API in global supply chains:
| Supplier (company) |
Supply role in market |
Typical geography |
Notes relevant to procurement |
| AstraZeneca (via historical supply chains) |
Historically produced / supplied amiodarone products |
EU/UK |
Many markets historically sourced from brand supply; many transitions to generics remain in place through legacy channels. |
| Teva |
Finished-dose supplier (sources generic API) |
Israel/Global |
Large-volume generic channel; product supply depends on chosen API sources per site. |
| Sandoz (Novartis) |
Finished-dose supplier (sources generic API) |
EU/Global |
Uses qualified API supply for tablet and injection lines. |
| Accord Healthcare |
Finished-dose supplier (sources generic API) |
UK/Global |
Common in EU and other markets for amiodarone products. |
| Mylan / Viatris |
Finished-dose supplier (sources generic API) |
Global |
Multi-site sourcing; product availability varies by country. |
| Siegfried (when used for generics/contract manufacture) |
Contract manufacturing for finished products |
EU |
Where engaged, supplies through finished dose rather than as standalone API. |
Procurement reality: for amiodarone hydrochloride, direct API sourcing is frequently handled through qualified distributors or through finished-dose manufacturers that control the supply chain and component qualification, especially for sterile injection presentations.
Which contract manufacturers (CMOs/CDMOs) supply finished amiodarone products?
If procurement targets finished product supply (tablets and injections), the practical supplier set is CDMOs and finished-dose generics with established sterile capabilities.
| Supplier type |
Typical deliverable |
What procurement should verify |
| Generic finished-dose manufacturers |
Tablets, and in many cases injections |
Strength, dosage form, sterile grade qualification, batch release sites |
| Sterile injectables CMOs/CDMOs |
Ampoules/vials filled and finished |
Sterility assurance, container closure system, cold-chain needs (if any) |
| Tableting CMOs |
Tablets |
Blending validation and stability handling for amiodarone hydrochloride |
For sterile presentations, supplier selection is driven by aseptic processing capability and batch release systems, not only API cost.
Which distributors commonly carry amiodarone hydrochloride?
In many jurisdictions, API is sourced through distribution networks that hold multiple DMF-backed generic inputs. These distributors typically do not “manufacture” the API; they aggregate supply from qualified sites and provide documentation (CoA, GMP letters, compliance packages).
| Distributor category |
Role |
What typically drives selection |
| Global life science distributors |
API and excipient distribution |
Documentation completeness, track record for market continuity |
| Regional wholesalers for hospital procurement |
Finished-dose supply |
Contract pricing, tender qualification, delivery SLA |
| Specialty injectables distributors |
Sterile supply chains |
Temperature control logistics and traceability |
How do API and finished-dose sourcing differ for amiodarone hydrochloride?
| Requirement |
API sourcing |
Finished-dose sourcing |
| Regulatory framing |
DMF/CEP/EDMF or local API registration |
Marketing authorization alignment per country (product dossier, GMP) |
| Quality documentation |
CoA, GMP/manufacturing site qualification |
CoA, batch release, sterile sterility assurance (for injection) |
| Supply continuity risk |
Intermediate availability and conversion to hydrochloride salt |
Filling capacity, aseptic lines, compendial compliance |
| Commercial decision |
Route economics and yield, but also qualification time |
Lead-time, tender/contract structure, and stability commitments |
What should buyers confirm during supplier qualification?
Even for an established generic like amiodarone hydrochloride, procurement is gated by documentation and manufacturing controls. Qualification packages typically include:
- GMP status and manufacturing site audit coverage for the API and (for sterile dosage) the finished form
- DMF/CEP/EDMF alignment with the intended market and dossier needs
- Particle size and polymorph controls (relevant for dissolution and stability)
- Salt form confirmation and impurity profile consistency across batches
- Stability data for the intended dosage form and packaging
Key Takeaways
- Amiodarone hydrochloride supply is dominated by generic, multi-source manufacturers; “supplier” is typically a function of whether buyers procure API or finished-dose product.
- For finished injections, supplier selection is constrained by sterile manufacturing and aseptic batch release capability.
- Buyers should qualify suppliers around DMF/CEP alignment, impurity profile control, and salt-form consistency, then lock supply via contract distributors or directly with established generic manufacturers.
FAQs
-
Is amiodarone hydrochloride still protected by patents in most markets?
No, it is widely treated as a generic API in ongoing commercial supply, with brand-origin products having long since lost exclusivity.
-
Do amiodarone injection suppliers source the same API as tablets?
Usually the API is the same substance, but procurement may differ because sterile manufacturing site qualification and documentation requirements differ.
-
What matters most when qualifying an amiodarone hydrochloride API supplier?
GMP compliance, dossier alignment (DMF/CEP), impurity profile consistency, and evidence of robust salt-form control.
-
Can distributors provide a substitute API supplier without re-qualification?
Not in most regulated settings. Substitution typically requires internal change control and regulatory alignment depending on whether the buyer is using the API in a marketed dossier.
-
Where does supply risk typically come from for amiodarone hydrochloride?
It most often comes from intermediate supply and conversion steps, and from sterile filling line constraints for injection products.
References
[1] European Medicines Agency (EMA). Public assessment reports and product information for amiodarone-containing medicines. https://www.ema.europa.eu/
[2] U.S. FDA. Drug approvals and labeling for amiodarone hydrochloride products (access via Drugs@FDA). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[3] FDA. Drug Master Files (DMF) overview and regulatory background. https://www.fda.gov/drugs/datasources/drug-master-files-dmf
[4] European Directorate for the Quality of Medicines and Healthcare (EDQM). CEP information (European Certificates of Suitability). https://www.edqm.eu/
